MacroGenics Provides Vobramitamab Duocarmazine Update
July 30, 2024 16:10 ET
|
MacroGenics, Inc.
Abstract of clinical data accepted for poster presentation at ESMO Congress 2024 in SeptemberESMO poster to include protocol-defined TAMARACK Phase 2 mCRPC study data, including pre-defined landmark...
MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results
August 09, 2023 16:01 ET
|
MacroGenics, Inc.
Advancing enrollment of TAMARACK Phase 2 study in metastatic castration-resistant prostate cancer (mCRPC) under revised protocol Initiating lorigerlimab Phase 2 study in mCRPC patients Achieved $50...